课题基金 / 基金详情

Development of ferroptosis inhibitors for Huntington Disease

Development of ferroptosis inhibitors for Huntington Disease
亨廷顿病铁死亡抑制剂的开发
批准号:
10461960
负责人:
Brent R Stockwell
金额:
$38.81万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-08-15 至 2023-07-31

项目摘要

项目成果

Brent R Stockwell的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Ferrostatin is a potent inhibitor of ferroptosis; which is a non-apoptotic form of cell death potentially involved in a number of degenerative diseases. We have shown the effectiveness of Fer-1 in brain slice models of Huntington's disease (HD) and glutamate toxicity. However, ferrostatin's pharmacokinetic/pharmacodynamic (PK/PD) properties make it unsuitable for use in animal models to further test the role of ferroptosis in these diseases. We have made a series of ferrostatin analogs to explore ferrostatin's structure-activity relationship (SAR) and to improve activity and metabolic and plasma stability. While we have made significant progress in creating metabolically stable analogs with good potency and plasma stability, additional improvements are envisioned that could result in highly potent, stable compounds that could be dosed in vivo. The result of this investigation will be a set of optimized compounds for in vivo use to study the role of lipid peroxidation in a mouse model of Huntington Disease. In the longer term, we will be able to use these optimized compounds to probe the role of lipid peroxidation and ferroptosis in a variety of degenerative diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of ferroptosis inhibitors for Huntington Disease
Multimodal mass spectrometry imaging of mouse and human liver
Multimodal mass spectrometry imaging of mouse and human liver
Multimodal mass spectrometry imaging of mouse and human liver
海外基金